The main purpose of the present study is to investigate the risk factors that affect drug pharmacokinetic (PK) during extracorporeal membrane oxygenation (ECMO). To advance understanding of PK variance and improve the patients outcomes during ECMO.
Ex vivo experiments for drug stability testing and ECMO circuits testing in animal models.PK studies in healthy animals and critically ill animal models with or without ECMO to define the PK alterations. Clinical PK studies in critically ill patients on ECMO.
Study Type
OBSERVATIONAL
Enrollment
50
Extracorporeal membrane oxygenation (ECMO) temporarily supports patients with severe cardio-respiratory failure
China-Japan Friendship hospital
Beijing, Beijing Municipality, China
RECRUITINGThe median observed peak concentration(Cmax)
Using liquid chromatography-mass spectrometry to evaluate the concentration of study drugs
Time frame: one-dose period
The median observed through concentration(Cmin)
Using liquid chromatography-mass spectrometry to evaluate the concentration of study drugs
Time frame: one-dose period
Volume of distribution(Vd)
PK data were analyzed with a nonlinear mixed-effect modeling approach using NONMEM version 7.2.0
Time frame: one-dose period
Area under the plasma concentration versus time curve (AUC)
PK data were analyzed with a nonlinear mixed-effect modeling approach using NONMEM version 7.2.0
Time frame: one-dose period
Inter-compartmental clearance (Q)
PK data were analyzed with a nonlinear mixed-effect modeling approach using NONMEM version 7.2.0
Time frame: one-dose period
Clearance(CL)
PK data were analyzed with a nonlinear mixed-effect modeling approach using NONMEM version 7.2.0
Time frame: one-dose period
Development of strategies for drug administration in critically ill patients receiving ECMO
PK models for study drugs using a non-linear mixed effects modeling approach.
Time frame: one-dose period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.